As of 2025-05-20, the Intrinsic Value of GT Biopharma Inc (GTBP) is -24.31 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.24 USD, the upside of GT Biopharma Inc is -1,185.23%.
Based on its market price of 2.24 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 1,185.23%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -24.31 - -24.31 | -24.31 | -1,185.23% |
| P/E | (115.32) - (225.20) | (132.73) | -6025.3% |
| DDM - Stable | (32.83) - (97.40) | (65.11) | -3006.9% |
| DDM - Multi | (28.91) - (69.92) | (41.28) | -1943.0% |
| Market Cap (mil) | 5.69 |
| Beta | 0.79 |
| Outstanding shares (mil) | 2.54 |
| Enterprise Value (mil) | 1.74 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.43% |
| Cost of Debt | 5.00% |
| WACC | 7.55% |